Stephane Fournier
Latest contributions
CathWorks FFRangio: from clinical data to advanced patient care
21 May 2026 – From EuroPCR 2026
Explore the clinical value of the CathWorks FFRangio system through the lens of the ALL-RISE randomised controlled trial and its implications for daily practice. By reviewing the trial’s primary and secondary endpoints, examine how FFRangio may influence diagnostic assessment, treatment planning, and clinical decision-making in patients...
Physiological vs. anatomical assessment of multivessel disease patients
21 May 2026 – From EuroPCR 2026
This session delves into the comparative benefits of physiological versus anatomical assessment in patients with multivessel coronary disease, focusing particularly on myocardial infarction cases. Attendees will explore how coronary physiology can guide complete revascularisation, the added value of physiological assessment beyond conventional angiography, and the selection...
Coronary innovations and artificial intelligence: new devices, smarter tools, better outcomes
20 May 2026 – From EuroPCR 2026
This session provides a practical update on emerging coronary innovations and AI technologies, including next-generation calcium modification devices, bioresorbable scaffolds, sirolimus drug-coated balloons, and AI-driven coronary physiology and imaging tools. It offers a roadmap for integrating these advancements into clinical practice, addressing technology selection, reimbursement, training,...
Bioresorbable devices in clinical practice
19 May 2026 – From EuroPCR 2026
This session examines the evolving role of bioresorbable devices in coronary intervention, showcasing hybrid PCI strategies, novel applications in myocardial bridging, and innovative solutions for complex coronary lesions, including the use of bioadaptors and dual-device techniques.
Once you find microvascular disease, what do you actually do?
18 May 2026 – From EuroPCR 2026
Addressing coronary microvascular disease requires a comprehensive understanding of current medical therapies and emerging interventions. This session reviews state-of-the-art pharmacological treatments, elucidates the mechanisms and clinical data surrounding the coronary sinus reducer (CSR), and offers critical discussion on its therapeutic role in microvascular dysfunction.